CME Group introduced Bitcoin Cash (BCH) and Uniswap (UNI) futures on October 19, 2026, expanding its crypto futures offerings to 11 products. BCH futures saw a brief rally after the announcement but open interest returned to pre-announcement levels by launch day, indicating short-term speculation rather than sustained demand. UNI futures had a quieter market response, but their launch is significant as it starts a six-month futures trading history required for potential ETF applications. Traders should watch early volume and open interest, especially in Micro contracts, to gauge broader market interest beyond large players.
Bitcoin Cash and Uniswap futures debut on October 19, 2026. For readers following cryptocurrency markets, here is Pluang's snapshot as of Oct 19, 2026 23:31 WIB: 41 of 50 major cryptocurrencies rose today. Bitcoin Cash (BCH) traded at Rp5.011.670 with a 3.75% increase. Pluang order activity for BCH showed 77% sell and 23% buy, with a typical hold time of 69 days. Tezos and The Graph also rose by 3.51% and 3.46% respectively.
Disc Medicine's stock surged 38% following positive Phase 3 trial results for its drug bitopertin, which showed efficacy and safety in treating erythropoietic protoporphyria. BMO Capital raised its price target from $100 to $120 and maintained an Out...
Qualcomm executive Ann C. Chaplin sold 1,827 shares of the company's stock for $319,268.25 under a Rule 10b5-1 trading plan, reducing her holdings by 6.62%. Qualcomm's stock price recently traded below its 50-day and 200-day moving averages, signalin...
BOK Financial is set to announce its Q3 2026 earnings after market close on October 19, with analysts forecasting earnings per share between $2.52 and $2.54 and revenue near $571 million. The company has a strong history of surpassing earnings estima...
AIBotics has completed the acquisition of NovaCore Labs' assets from PlayJamaica Limited, gaining technology, software, drones, mapping equipment, and customer contracts. This move expands AIBotics' platform in Jamaica and the Caribbean, enhancing AI...
EyePoint's stock dropped sharply after its DURAVYU treatment did not meet the primary endpoint in a Phase 3 trial for wet age-related macular degeneration (wet AMD). Although DURAVYU showed some vision improvement and reduced the need for additional ...
